Holista CollTech Limited announced that it has been granted permission under Special access under the Medical Device (Exemption) Order 2016, from the Medical Devices Authority ("MDA") of Malaysia's Ministry of Health ("MOH") to import and distribute for an antigen rapid test kit (RTK-AG) developed and manufactured by Guangdong Hecin Scientific Inc. ("Hecin") of China. With this approval, the Company has secured an initial order for 15,000 units worth $95,000.00 in Malaysia. The test kits will be used to detect the presence of the SARS-CoV-2 viral antigen from nasal swabs within 15 minutes. It is for screening purposes by healthcare professionals and not the sole basis for diagnosis and exclusion decisions. The maiden order was secured by the Company's wholly owned subsidiary Holista Biotech Sdn. Bhd. from Klinik Mutiara, which is part of Amegajaya Sdn Bhd, a medical consultancy that works closely with MOH and related agencies in Malaysia. With the MDA permission, Holista is only permitted to sell and supply the test kits to the registered healthcare professional at Klinik Mutiara. MDA has stipulated that Holista can import up to 45,000 units of the antigen rapid test kits to Malaysia within the first three months of the permission for importation of medical devices for special access under the Medical Device (Exemption) Order dated 14 June 2021. The first 15,000 units will be shipped by end of June 2021. The order marks the first commercial transaction of SARS-CoV-2 test kits by the Company. Based in Guangzhou, Hecin has developed diagnostic products for nucleic acid, immunofluorescence, flow cytometry, as well as medical reagents, amongst others. Hecin has conducted clinical trials for the antigen test kits. The clinical trial was carried out in Daye City Center for Disease Control and Prevention within China. The clinical performance of Hecin RTK-Antigen test kit against Polymerase Chain Reaction (PCR) Comparator method using nasopharyngeal swabs specimens hasobtained a sensitivity of 96.23% and specificity 99.07% Note 1.